Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118

PUBT · 1d ago
Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118
  • Laekna began a Phase I study of LAE118 in China for advanced solid tumors, enrolling the first participant.
  • No clinical results were presented; the update focused on trial initiation rather than outcomes.
  • LAE118 targets PI3Kα mutations; development aims to assess early safety and activity without reporting performance metrics.
  • A June 2026 license with Vasque Bio includes up to USD 527 million in upfront and milestone payments, royalties on net sales.
  • Agreement also provides an equity option in Vasque Bio, with additional payments tied to certain partnering or acquisition transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260901-12310495), on September 01, 2026, and is solely responsible for the information contained therein.